JP2014521605A - Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物 - Google Patents

Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物 Download PDF

Info

Publication number
JP2014521605A
JP2014521605A JP2014521610A JP2014521610A JP2014521605A JP 2014521605 A JP2014521605 A JP 2014521605A JP 2014521610 A JP2014521610 A JP 2014521610A JP 2014521610 A JP2014521610 A JP 2014521610A JP 2014521605 A JP2014521605 A JP 2014521605A
Authority
JP
Japan
Prior art keywords
vaccine
staphylococcus aureus
als3p
use according
candida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521605A5 (enExample
Inventor
マイケル アール． イーマン，
ジョン イー． ジュニア エドワーズ，
スコット ジー． フィラー，
アシュラフ エス． イブラヒム，
ユエ フー，
ジョン ピー． ジュニア ヘネシー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2014521605A publication Critical patent/JP2014521605A/ja
Publication of JP2014521605A5 publication Critical patent/JP2014521605A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014521610A 2011-07-22 2012-07-20 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物 Pending JP2014521605A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
US61/510,896 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (2)

Publication Number Publication Date
JP2014521605A true JP2014521605A (ja) 2014-08-28
JP2014521605A5 JP2014521605A5 (enExample) 2015-08-27

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521610A Pending JP2014521605A (ja) 2011-07-22 2012-07-20 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物

Country Status (12)

Country Link
US (1) US10653757B2 (enExample)
EP (1) EP2734229B1 (enExample)
JP (1) JP2014521605A (enExample)
CN (1) CN103998056B (enExample)
AU (1) AU2012287513A1 (enExample)
BR (1) BR112014001409A2 (enExample)
CA (1) CA2842626A1 (enExample)
EA (1) EA035513B1 (enExample)
ES (1) ES2716800T3 (enExample)
GE (1) GEP201706766B (enExample)
UA (1) UA114286C2 (enExample)
WO (1) WO2013015831A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507759A (ja) * 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
UA114286C2 (uk) 2011-07-22 2017-05-25 Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" Спосіб лікування staphylococcus aureus
WO2014153241A1 (en) * 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
CN105263513A (zh) * 2013-03-14 2016-01-20 王荣福 调控调节性t细胞功能的方法和组合物
CN105407915A (zh) * 2013-03-15 2016-03-16 加州大学洛杉矶分校港口医学中心生物医学研究所 用于治疗真菌性和细菌性病原体的组合物和方法
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
WO2019113096A1 (en) 2017-12-05 2019-06-13 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN112203684A (zh) * 2018-04-10 2021-01-08 海港医学中心洛杉矶生物医学研究所 耳念珠菌感染的治疗方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用
WO2025032534A2 (en) * 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025240443A1 (en) * 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124134A1 (en) * 1999-11-19 2003-07-03 Harbor-Ucla Research And Education Institute Pharmaceutical compositions and methods to vaccinate against candidiasis
JP2007512312A (ja) * 2003-11-21 2007-05-17 ファイザー・プロダクツ・インク ワクチンアジュバントとしての抗生物質の使用
JP2009524601A (ja) * 2006-01-06 2009-07-02 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964721D1 (en) 1978-08-24 1983-03-17 Nat Res Dev Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
EP0702516A4 (en) 1993-06-01 1998-04-22 Life Technologies Inc GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
PT831897E (pt) 1995-06-07 2001-07-31 Pfizer Vacinacao in ovo contra a coccidiose
AU3126097A (en) 1996-05-16 1997-12-05 The Texas A & M University System Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
EP3269235B1 (en) 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
CN101596312A (zh) 2002-05-21 2009-12-09 先灵-普劳有限公司 孢子纲物种体外培养的方法及其用途
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
WO2005060713A2 (en) 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
MX2008013451A (es) 2006-04-17 2008-10-30 Schering Plough Ltd Organismos clostridium atenuados recombinantes y vacuna.
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
RU2525587C2 (ru) 2008-05-29 2014-08-20 Интервет Интернэшнл Б.В. Вакцинная композиция для иммунизации животного против кокцидиоза и способ ее использования
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
RU2559537C2 (ru) 2009-07-03 2015-08-10 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Hyr1 в качестве мишени для активной и пассивной иммунизации против candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
UA114286C2 (uk) 2011-07-22 2017-05-25 Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" Спосіб лікування staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124134A1 (en) * 1999-11-19 2003-07-03 Harbor-Ucla Research And Education Institute Pharmaceutical compositions and methods to vaccinate against candidiasis
JP2007512312A (ja) * 2003-11-21 2007-05-17 ファイザー・プロダクツ・インク ワクチンアジュバントとしての抗生物質の使用
JP2009524601A (ja) * 2006-01-06 2009-07-02 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530786A (ja) * 2009-06-22 2012-12-06 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507759A (ja) * 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Also Published As

Publication number Publication date
UA114286C2 (uk) 2017-05-25
GEP201706766B (en) 2017-10-25
AU2012287513A8 (en) 2014-06-19
US20150273031A1 (en) 2015-10-01
US10653757B2 (en) 2020-05-19
ES2716800T3 (es) 2019-06-17
EA201391200A1 (ru) 2014-05-30
BR112014001409A2 (pt) 2017-07-11
CN103998056A (zh) 2014-08-20
EP2734229B1 (en) 2019-01-02
WO2013015831A1 (en) 2013-01-31
EP2734229A1 (en) 2014-05-28
CA2842626A1 (en) 2013-01-31
AU2012287513A1 (en) 2014-03-13
EA035513B1 (ru) 2020-06-29
CN103998056B (zh) 2017-09-12
EP2734229A4 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
US10653757B2 (en) Methods and compositions for vaccinating against Staphylococcus aureus
JP6167130B2 (ja) Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
Portuondo et al. A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection
Wang et al. Vaccines in the treatment of invasive candidiasis
JP2019507759A (ja) 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
Dutta et al. Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles
JP2019110918A (ja) 真菌病原体および細菌病原体を処置するための組成物および方法
US10160790B2 (en) HYR1-derived compositions and methods of treatment using same
JP6655549B2 (ja) 免疫応答を誘導するための新規方法
JP2017513849A (ja) Ａ群レンサ球菌ワクチン
Luo et al. mRNA-based platform for preventing and treating Staphylococcus aureus by targeted staphylococcal enterotoxin B
KR20160020543A (ko) 씨. 디피실에 대해서 면역화시키는 조성물 및 방법
Souza et al. Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis
US20160030533A1 (en) Compositions and methods of treating fungal and bacterial pathogens
JP2020028219A (ja) マラリアワクチン
CN121015856A (zh) 一种呼吸道合胞病毒疫苗组合物
Khodadad et al. A comprehensive review of neurotropic fungal infections: clinical manifestations and vaccines
Smith et al. Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect
JP2025520500A (ja) 免疫活性部位融合タンパク質を含む結核ワクチン組成物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160921